Theriva Biologics, Inc. (TOVX)
NYSE: TOVX · Pharmaceutical Preparations · Rockville, MD · filing with the SEC since 1996
Who owns Theriva Biologics, Inc.
As filed with the SECHolders of 5% or more
1
Jeffrey Matthew Gryga Irrevocable Trust holds 7.7% of Common stock, as its SCHEDULE 13G filed Nov 10, 2025 says.
Directors and officers
4
report now, of 8 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Jeffrey Matthew Gryga Irrevocable Trust
SCHEDULE 13G · filed Nov 10, 2025 · Common stock
Empery Asset Management, LP
SCHEDULE 13G/A · filed Oct 21, 2025 · Common Stock, $0.001 par value per share · reported falling below 5%, from 9.99% in Jul 31, 2025
CVI Investments, Inc.
SCHEDULE 13G/A · filed Feb 7, 2025 · Common Stock, $0.001 par value per share · reported falling below 5%
What TOVX reports owning in othersstakes of 5% or more, and other ties
9 subsidiaries in 2 countries, from the list filed with the 10-K filed Mar 6, 2025.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2023 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.